PALVELLA THERAPEUTICS, INC.PVLAEarnings & Financial Report
Nasdaq
PVLA Q3 2025 Key Financial Metrics
Revenue
$628.0K
Gross Profit
N/A
Operating Profit
$-10.2M
Net Profit
$-11.3M
Gross Margin
N/A
Operating Margin
-1620.5%
Net Margin
-1806.5%
YoY Growth
N/A
EPS
$-1.03
Financial Flow
PALVELLA THERAPEUTICS, INC. Q3 2025 Financial Summary
PALVELLA THERAPEUTICS, INC. reported revenue of $628.0K for Q3 2025, with a net profit of $-11.3M (-1806.5% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $628.0K |
|---|---|
| Net Profit | $-11.3M |
| Gross Margin | N/A |
| Operating Margin | -1620.5% |
| Report Period | Q3 2025 |
PALVELLA THERAPEUTICS, INC. Annual Revenue by Year
PALVELLA THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2023 revenue was $42.8M).
| Year | Annual Revenue |
|---|---|
| 2023 | $42.8M |
| 2022 | $25.9M |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $1.3M | $53000 | $0 | $0 | $752000 | $690000 | $628000 |
| YoY Growth | 263.5% | -77.8% | -97.3% | N/A | N/A | 1318.9% | N/A | N/A |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $59.4M | $38.7M | $29.5M | $25.1M | $20.5M | $79.4M | $73.7M | $66.9M |
| Liabilities | $28.9M | $11.9M | N/A | N/A | N/A | $23.9M | $26.0M | $28.3M |
| Equity | $30.5M | $26.8M | $22.0M | $18.7M | $16.3M | $55.6M | $47.8M | $38.7M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-9.7M | $-19.7M | $-7.0M | $-1.5M | $146000 | $-6.8M | $-5.4M | $-7.9M |